Phenix Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 27-06-2024
- Paid Up Capital ₹ 0.10 M
as on 27-06-2024
- Company Age 17 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -30.71%
(FY 2022)
- Profit -46.58%
(FY 2022)
- Ebitda -82.22%
(FY 2022)
- Net Worth 335.95%
(FY 2022)
- Total Assets 28.12%
(FY 2022)
About Phenix Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Hitesh Patel, Amit Patel, and Prashant Pandya serve as directors at the Company.
- CIN/LLPIN
U24232GJ2007PTC051738
- Company No.
051738
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Sep 2007
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Vadodara, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media
What products or services does Phenix Pharma Private Limited offer?
Phenix Pharma Private Limited offers a wide range of products and services, including Hand Sanitizers & Personal Hygiene, Hand Sanitizer & Disinfectant, Multivitamin Tablets & Capsules, Cough Syrup, Antibiotic Tablets & Capsules, Cefixime Tablet, Amoxicillin drugs, Amoxicillin Capsule, Mineral Supplement, Zinc Capsule.
Who are the key members and board of directors at Phenix Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Hitesh Patel  | Director | 05-Jul-2008 | Current |
| Amit Patel | Director | 05-Jul-2008 | Current |
| Prashant Pandya | Director | 14-Sep-2007 | Current |
Financial Performance and Corporate Structure Insights of Phenix Pharma.
Phenix Pharma Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 30.71% decrease. The company also saw a substantial fall in profitability, with a 46.58% decrease in profit. The company's net worth Soared by an impressive increase of 335.95%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Phenix Pharma?
In 2021, Phenix Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Phenix Pharma?
Unlock and access historical data on people associated with Phenix Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Phenix Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Phenix Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
